<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763958</url>
  </required_header>
  <id_info>
    <org_study_id>R21DA019838</org_study_id>
    <secondary_id>5R21DA019838-03</secondary_id>
    <secondary_id>7R21DA019838-02</secondary_id>
    <nct_id>NCT00763958</nct_id>
  </id_info>
  <brief_title>Relapse Prevention to Reduce HIV Among Women Prisoners</brief_title>
  <official_title>Relapse Prevention to Reduce HIV Among Women Prisoners</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a feasibility and acceptability study assessing whether providing buprenorphine
      for women under criminal justice supervision leaving a controlled environment and returning
      to the community would prevent opioid relapse and reduce HIV risk behaviors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study sought to enroll opioid dependent women under supervision in the criminal justice
      system and in a controlled environment (substance abuse treatment)but at at high risk for
      opioid relapse and engaging in HIV risk behaviors when returning to the community. Initially,
      9 women were enrolled and received buprenorphine medication. After the first 9 participants,
      women were randomized to either buprenorphine or placebo. Women received the buprenorphine
      medication for 12 weeks in the community and at the end of the 12 weeks were transitioned
      either to another buprenorphine provider, methadone provider, or tapered off buprenorphine
      based on the participant's preferences. One additional follow-up at 3 months after treatment
      was conducted. The primary outcome was opioid positive urines at all time points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opiate Positive Urines With Missing Urines Coded as Positive at Week 12.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with positive opiate urine samples at 12 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opiate Positive Urines With Missing Urines Coded as Positive at Week 24.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with positive opiate urine sample at the 24 week follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Enroll in the Study.</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To determine the number of participants who enroll in the study during the time of recruitment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Opioid Dependence</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo sublingual medication provided to individuals randomized to control up to 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match buprenorphine administered for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female,

          -  history of opioid dependence,

          -  released back to the community from a controlled environment,

          -  criminal justice involvement.

        Exclusion Criteria:

          -  under age 19,

          -  medical contraindications,

          -  major psychiatric problems.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <results_first_submitted>February 4, 2011</results_first_submitted>
  <results_first_submitted_qc>May 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2012</results_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Karen Cropsey</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>opiates</keyword>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in May of 2008 and ended June of 2010. All participants were recruited from a 28-day drug inpatient facility that accepts patients from the criminal justice system.</recruitment_details>
      <pre_assignment_details>Initially, 11 women were enrolled in the open-label trial, followed by 33 women randomized to either buprenorphine or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Buprenorphine provided for 12 weeks up to 32 mg daily based on clinical assessment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Medication &quot;sugar pill&quot; provided for 12 weeks up to 32 mg daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not meet final criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Believed they were receiving placebo</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Buprenorphine provided for 12 weeks up to 32 mg daily based on clinical assessment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Medication &quot;sugar pill&quot; provided for 12 weeks up to 32 mg daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="6.6"/>
                    <measurement group_id="B2" value="34.7" spread="10.3"/>
                    <measurement group_id="B3" value="31.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opiate Positive Urines With Missing Urines Coded as Positive at Week 12.</title>
        <description>Number of participants with positive opiate urine samples at 12 weeks of treatment.</description>
        <time_frame>12 weeks</time_frame>
        <population>All subjects were included in the analysis population as intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine provided for 12 weeks of study drug based on clinical assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Medication &quot;sugar pill&quot; provided for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Opiate Positive Urines With Missing Urines Coded as Positive at Week 12.</title>
          <description>Number of participants with positive opiate urine samples at 12 weeks of treatment.</description>
          <population>All subjects were included in the analysis population as intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Enroll in the Study.</title>
        <description>To determine the number of participants who enroll in the study during the time of recruitment.</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine provided for 12 weeks of stuty drug based on clinical assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Medication &quot;sugar pill&quot; provided for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Enroll in the Study.</title>
          <description>To determine the number of participants who enroll in the study during the time of recruitment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Opiate Positive Urines With Missing Urines Coded as Positive at Week 24.</title>
        <description>Number of participants with positive opiate urine sample at the 24 week follow-up.</description>
        <time_frame>24 weeks</time_frame>
        <population>All subjects were included in the analysis population as intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine provided for 12 weeks of study drug based on clinical assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Medication &quot;sugar pill&quot; provided for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Opiate Positive Urines With Missing Urines Coded as Positive at Week 24.</title>
          <description>Number of participants with positive opiate urine sample at the 24 week follow-up.</description>
          <population>All subjects were included in the analysis population as intent to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Buprenorphine provided for 12 weeks up to 32 mg daily based on clinical assessment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Medication &quot;sugar pill&quot; provided for 12 weeks up to 32 mg daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Slow recruitment with poor retention. Transient population that was difficult to effectively track.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Karen Cropsey</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-917-3786 ext 205</phone>
      <email>kcropsey@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

